Biofrontera AG (BFRA) and Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) Contrasting side by side

We will be comparing the differences between Biofrontera AG (NASDAQ:BFRA) and Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) as far as analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biofrontera AG 15 0.00 N/A -0.76 0.00
Rigel Pharmaceuticals Inc. 2 4.21 N/A -0.39 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows Biofrontera AG and Rigel Pharmaceuticals Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Biofrontera AG 0.00% 0% 0%
Rigel Pharmaceuticals Inc. 0.00% -58.9% -44.2%

Institutional & Insider Ownership

Biofrontera AG and Rigel Pharmaceuticals Inc. has shares held by institutional investors as follows: 2.04% and 96.2%. Insiders held roughly 0.04% of Biofrontera AG’s shares. On the other hand, insiders held about 0.25% of Rigel Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Biofrontera AG -5.81% -11.18% 28.16% 14% 2.71% 32.89%
Rigel Pharmaceuticals Inc. -6.94% -9.88% 3.17% 5.07% -17.99% -0.87%

For the past year Biofrontera AG had bullish trend while Rigel Pharmaceuticals Inc. had bearish trend.

Summary

Biofrontera AG beats on 4 of the 7 factors Rigel Pharmaceuticals Inc.

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and Daiichi Sankyo to pursue research related to ligases. The company was founded in 1996 and is based in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.